Plasma-SeqSensei™ Melanoma RUO Kit
Plasma-SeqSensei™ Melanoma RUO Kit
- Highly sensitive down to 0.07 % MAF
- Able to detect 7 MM with 95 % confidence across all mutations (absolute quantification)
- High flexibility of between 2 - 16 samples/run
- Fast TAT (2 days)
- Convenient software
The Plasma-SeqSensei™ (PSS) Melanoma RUO (research use only) Kit allows the highly sensitive and specific detection of mutations in circulating tumour DNA (ctDNA) from plasma of patients with melanoma cancer.
The kit is based on the next-generation sequencing technology and covers key mutations of the BRAF and NRAS oncogenes. These genes have been shown to enhance tumour growth, promote disease progression and can be considered prognostic and predictive biomarkers in melanoma. [1-2]
BRAF mutations are present in approximately 50% of all melanomas (~ 90% of these mutations occur at amino acid 600, majority of which are BRAF V600E mutations). [3]
Mutations in NRAS are currently known to be present in 20% of all melanomas (majority (>80%) involve a point mutation leading to the substitution of glutamine to leucine at position 61). [4]
For the configuration of the Plasma-SeqSensei™ Melanoma RUO Kits, two key cancer genes were selected after comparison of mutation frequencies using the COSMIC (Catalogue of Somatic Mutation in Cancer) and cBioPortal for cancer genomics databases.
Mutation frequencies are listed in the table below:
Skin cancer
| COSMIC [5] | cBioPortal [6] | |
| BRAF | 42.1% | 51.0% |
| NRAS | 15.4% | 24.0% |
Most frequent mutations detected by Plasma-SeqSensei™ Melanoma RUO panel:
| Gene ID | Most frequent mutations in melanoma |
| BRAF | V600E, V600K, V600R, V600E |
| NRAS | Q61K, Q61R, Q61L, G12D |
Plasma-SeqSensei™ Melanoma RUO Kit is intended for research use only. Diagnostic use is not supported.
References
- Helgadottir et al. Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. Frontiers in Oncology 8(202), 1-15, 2018.
- Marczynski et al. Circulating tumor DNA (ctDNA) detection is associated with shorter progression‑free survival in advanced melanoma patients. Scientific Reports 10, 1-11, 2020.
- Gonzalez et al. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. Br J Dermatol 168(4), 700-707, 2013.
- Milagre et al. A mouse model of melanoma driven by oncogenic KRAS. Cancer Research 70(13), 5549-5557, 2010.
- https://cancer.sanger.ac.uk/cosmic
- https://www.cbioportal.org/
Sysmex Europe SE
Bornbarch 1
22848 Norderstedt
Germany
+49 (40) 527 26 0
+49 (40) 527 26 100
Product documents
Regulatory documents
Regulatory documents, such as Instructions for Use, can be accessed with a valid My Sysmex login:
Go to My Sysmex
